We believe all people are created equal, and we reject racism and bigotry.
Who We Are
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases. We do this by:
Finding the right starting points to target diseases at their source. Using a combination of a systematic assessment of the genetic disease landscape and informed diligence on the latest research, we find indications with clear mechanisms of pathogenesis that are ripe for translation into disease-modifying drugs.
Building products with world-class R&D personnel. We employ over 50 scientists and work closely with leading academics to prosecute a wide variety of drug programs at the highest level of scientific rigor. We combine biopharmaceutical veterans with up-and-coming leaders to drive entrepreneurial thinking grounded by experience.
Employing a lean, capital efficient model. We house each effort in an individual subsidiary company supported by shared central resources. This efficient, de-centralized corporate structure enables focus at level of each disease, but provides diversification and the ability to scale across many opportunities.
Our core values are:
Put Patients First
Do Everything as Fast as Possible
Be Radically Transparent
Starting with Today‘s Insights to Make Tomorrow’s Medicines
A changing scientific and clinical landscape allows our unique corporate model to efficiently create products that address significant disease burdens.
Exome and whole genome sequencing (cost and quality)Molecular biology and pathway mappingExtreme PhenotypingBig data and patient registriesDeep sequencingVariant calling and bioinformatics
Find well described high unmet diseases that are ripe for interventionDevelop medicines that target genetic drivers directly (at the source)Operate with world-class R&D capabilities and personnel that have developed significant, marketed productsEmploy a scale-able and low cost corporate structure
Disease modifying products that help patients with significant disease
BridgeBio Business Unit
Cardiology / Neurology
PANK2 (pantothenate kinase)
Pantothenate kinase activator
Multiple tumor types
PTPN11 (SHP2) and MAPK pathway
Multiple tumor types
RAF1 (C-RAF) and MAPK pathway
Multiple tumor types
KRAS and MAPK pathway
Dermatology / Oncology
Frequent basal cell carcinoma
PTCH1 (patched-1, a smoothened inhibitor)
Dystrophic epidermolysis bullosa
COL7A1 (collagen 7)
Collagen 7 replacement
Protein replacement therapy
SPINK5 (LEKT1, a kallikrein 5/7/14 inhibitor)
Kallikrein 5/7/14 inhibitor
Laura Brege Marta Cruz Jonathan Fox, MD, PhD Bruno Gagnon Michael Henderson, MD Charles Homcy, MD Hoyoung Huh, MD, PhD Jesper Jernelius, PhD Neil Kumar, PhD Andrew Lo, PhD Frank McCormick, PhD Michael Pettigrew Len Post, PhD
Asha Rajagopal, CPA
Satish Rao, PhD Phil Reilly, MD, JD Hector Rodriguez, PhD Richard Scheller, PhD* Uma Sinha, PhD Sabina Sood Kahlil D’Souza
Justin To Cameron Turtle, DPhil Dru van Dam Shafique Virani, MD Robert Zamboni, PhD
* = Special Advisor
Board of Directors
Neil Kumar (BridgeBio Pharma) Jim Momtazee (KKR) Ali Satvat (KKR) Rohan Nirody (Observer, Viking Global Investors) Eric Aguilar (Observer, Aisling Capital) Doug Dachille (Observer, AIG)
BridgeBio is committed to creating leaders as well as drugs. Our continued growth and success depends on recruiting and retaining top talent who share our mission and values. In particular, we are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and an ability to seek out novel solutions in the face of adversity. If you are interested in joining the BridgeBio team, please contact us at email@example.com
BridgeBio is on the lookout for partners with whom we can establish new programs or collaborate on our existing projects that aim to make a meaningful difference for patients with genetic diseases.
If you have an investment opportunity in which we might be interested, please contact Michael Henderson (firstname.lastname@example.org). For interest in any current BridgeBio program, please contact Cameron Turtle (email@example.com).